MetaCap

Telix Pharmaceuticals (TLX) vs Zai Lab (ZLAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zai Lab (ZLAB) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 5.0% versus a loss of 6.1%. Telix Pharmaceuticals is the larger company by market cap ($2.84 billion vs $2.63 billion), about 1.1 times the size. Telix Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.9% versus -38.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TLX-6.06%ZLAB+5.04%
+48%+8%-32%
Nov 21, 20251 yearNov 20, 2026
TLX-43.64%ZLAB-22.28%
+57%-2%-61%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TLX versus ZLAB key metrics
MetricTLXZLAB
Share price$8.37$21.03
Market cap$2.84B$2.63B
1-day change-3.90%-4.06%
YTD return+11.75%+19.22%
1-year return-6.06%+5.04%
5-year return—-72.67%
P/E ratio (TTM)83.70—
EPS (TTM)$0.10$-1.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$803.79M$460.16M
Revenue growth (YoY)+55.61%+15.33%
Net income (latest FY)$-7.13M$-175.54M
Gross margin53.05%58.60%
Operating margin3.70%-49.86%
Net margin-0.89%-38.15%
52-week high$13.11$29.02
52-week low$6.28$15.96
Distance from 52-week high-36.16%-27.53%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+134.89%+62.67%
Average volume356.74K991.34K
Shares outstanding339.78M124.84M
Employees1,1201,784
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZLAB has outperformed TLX by 11.1 percentage points over the past year.
  • Telix Pharmaceuticals is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -38.1 cents for Zai Lab.
  • Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs +15.33%).

About Telix Pharmaceuticals

TLX stock →

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees

About Zai Lab

ZLAB stock →

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees

TLX vs ZLAB FAQ

Which is bigger, Telix Pharmaceuticals or Zai Lab?

Telix Pharmaceuticals (TLX) is larger, with a market capitalization of $2.84B compared with $2.63B for Zai Lab (ZLAB).

Which stock has performed better over the past year, TLX or ZLAB?

ZLAB returned +5.04% over the past 12 months, compared with -6.06% for TLX (price return, excluding dividends). Past performance does not predict future results.

Are Telix Pharmaceuticals and Zai Lab in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons